2020 Revenues ($USD) : $3,122,035,962
2020 Revenues (foreign currencies) : JP¥333,371,000,000
2020 R&D spend : $449,044,765
2020 Number of Employees : 5,233
Fiscal Year End : 3/31/2020
Key People : Isao Teshirogi, president & CEO

Shionogi is more than 140 years old. The Japanese pharma giant is focusing in the U.S. on developing and commercializing products to meet what it sees as unmet needs, including infectious diseases, pain and chronic liver disease. Shionogi in 2020 launched the siderophore cephalosporin antibiotic Fetroja (cefiderocol) in the U.S. –CN